Popular on eTradeWire
- Eduscape and Engino Join Forces to Solve the "E" Challenge in STEM Education - 336
- Southern Utah Retreats: The Hottest Retreat Center in the Southwest - 254
- Tevye in New York! at North Coast Rep Variety Nights - 251
- Local Roofer Advises OKC Homeowners on Hail-Resistant Roofing Options Following Recent Storms - 236
- TicketMeta and TechStorm Forge Strategic Partnership to Revolutionize Esports Event Experiences - 222
- Theralist Celebrates One Year Anniversary of Launch with Impressive Growth and Expansion - 211
- Another Reagan AP Accident; AI to the Rescue? - 207
- One Home Service Names Atlantic Harbor as Broward County's #1 Marine Construction Company - 193
- Revolutionary Partnership Bridging AI/Youth Sports/Business - 181
- Over 9,000 Users Trust QBSwift for Reliable QuickBooks Solutions - 170
Similar on eTradeWire
- $4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression, PTSD: NRx: Stock Symbol: NRXP
- Clinical Endpoints Successfully Met in Study for Groundbreaking 12-Lead ECG Synthesis Technology Allowing Software Application to FDA: HeartBeam, Inc
- LifeNome Launches Precision Longevity OS
- Streamline Drug Discovery Research Amerigo Scientific's Phosphorylation Assay Kits Offer Faster, Sim
- Adept Leadership Launches "Adept Culture"
- Manhattan Bio Announces Successful Validation Of Novel Legumain-Cleavable TOP1i ADC Platform
- Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD: NRx: (Stock Symbol: NRXP)
- NEXS BIOMEDICA CORPORATION Partners with Microsoft to Transform Biotechnology
- STEM Careers Unlocked Launches to Help STEM Professionals Fast-Track Career Success
- Lifenome Inc. and Optimo Life Launch Genetria, Transforming Precision Health and Longevity in Latin America
Ace Therapeutics' Diabetic Mouse Models Enable Research on Different Types of Diabetes
eTradeWire News/10773062
Ace Therapeutics is proud to announce the launch of its extensive suite of diabetic mouse models.
NEW YORK - eTradeWire -- Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models (https://www.acetherapeutics.com/diabetes/mouse-...). These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options.
Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). Diabetes can be categorized into three primary forms - type 1, type 2, and gestational diabetes - each with distinct underlying causes. With the prevalence of diabetes increasing at an alarming rate, there is a critical need for innovative research solutions to better understand and combat this epidemic. The use of mouse models enables the study of diabetes in a way that closely mirrors the disease in humans, helping to explore disease mechanisms, find biomarkers, and evaluate potential treatments.
More on eTradeWire News
Ace Therapeutics provides diverse diabetic mouse models targeting type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). The T1DM mouse models allow researchers to study the mechanism of type 1 diabetes, identify biomarkers, and test potential therapies. Mouse models for T2DM (https://www.acetherapeutics.com/diabetes/t2dm-mouse-models.html) study is generated by feeding mice a high-fat or high-sugar diet or genetically modifying mice to develop obesity and insulin resistance. These models matter a lot in type 2 diabetes research. Different from T2DM mouse models, GDM mouse models involve feeding mice a high-fat or high-sugar diet during pregnancy or genetically modifying mice to develop impaired glucose tolerance and insulin resistance during pregnancy.
"With the launch of our diabetic mouse models, we are excited to provide researchers with a reliable and versatile platform to advance their understanding of diabetes and develop novel treatments," said the marketing manager of Ace Therapeutics. "Our models offer a high level of accuracy and reproducibility, allowing for more precise and reliable results in preclinical studies."
More on eTradeWire News
Ace Therapeutics' mouse models mimic the key characteristics of human diabetes, such as hyperglycemia, insulin resistance, and pancreatic dysfunction, making them invaluable for investigating disease pathology and testing new therapeutics. These mouse models are available for purchase immediately and can be customized to meet specific research needs as well.
About Ace Therapeutics
Ace Therapeutics is a leading provider of preclinical research products and services, specializing in drug discovery and development for metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases.
Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). Diabetes can be categorized into three primary forms - type 1, type 2, and gestational diabetes - each with distinct underlying causes. With the prevalence of diabetes increasing at an alarming rate, there is a critical need for innovative research solutions to better understand and combat this epidemic. The use of mouse models enables the study of diabetes in a way that closely mirrors the disease in humans, helping to explore disease mechanisms, find biomarkers, and evaluate potential treatments.
More on eTradeWire News
- Titan Pressure Washing Demonstrates Why You Should Never Pressure Wash With Consumer Cleaning Products
- Celebrate Mother's Day in Style at Sheraton Albuquerque Uptown's Elegant Brunch Event
- The League Club Awards Goodwill SWFL $30K
- Harris Cleaning Services is the Ultimate Post-Construction Commercial Cleaning Service
- Immokalee Fair Housing Alliance awarded Non-Profit Impact of the Year
Ace Therapeutics provides diverse diabetic mouse models targeting type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). The T1DM mouse models allow researchers to study the mechanism of type 1 diabetes, identify biomarkers, and test potential therapies. Mouse models for T2DM (https://www.acetherapeutics.com/diabetes/t2dm-mouse-models.html) study is generated by feeding mice a high-fat or high-sugar diet or genetically modifying mice to develop obesity and insulin resistance. These models matter a lot in type 2 diabetes research. Different from T2DM mouse models, GDM mouse models involve feeding mice a high-fat or high-sugar diet during pregnancy or genetically modifying mice to develop impaired glucose tolerance and insulin resistance during pregnancy.
"With the launch of our diabetic mouse models, we are excited to provide researchers with a reliable and versatile platform to advance their understanding of diabetes and develop novel treatments," said the marketing manager of Ace Therapeutics. "Our models offer a high level of accuracy and reproducibility, allowing for more precise and reliable results in preclinical studies."
More on eTradeWire News
- K4Connect Partners with Thryve Health to Personalize Wellness Through Wearable Device Integration
- Global Learning Charter Public School to Hold Annual Global Gala Scholarship Fundraiser on May 9th
- PAG Law Represents Expeditionary Engineering Inc. in Strategic Acquisition by Ultra Intelligence & Communications
- Ketcham Racing Hosts Spring Car Show
- YourEggs Egg Donation Bank Launches Pride Eggs: A New Division Dedicated to Celebrating and Supporting LGBTQ+ Families
Ace Therapeutics' mouse models mimic the key characteristics of human diabetes, such as hyperglycemia, insulin resistance, and pancreatic dysfunction, making them invaluable for investigating disease pathology and testing new therapeutics. These mouse models are available for purchase immediately and can be customized to meet specific research needs as well.
About Ace Therapeutics
Ace Therapeutics is a leading provider of preclinical research products and services, specializing in drug discovery and development for metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases.
Source: Ace Therapeutics
Filed Under: Biotech
0 Comments
Latest on eTradeWire News
- Allergy, Asthma and Immunology Center Welcomes Dr. Karthik R. Krishnan, MD to Its Expanding Team
- Advot.org proudly announces another success story!
- Bavarian Inn Lodge hosting job fair for indoor waterpark and family fun center
- Ax3.ai Makes Strategic Equity Investment in Matrice.ai to Advance Global AI Infrastructure and Computer Vision Innovation
- Popular Kiwanis Danville 4th of July Parade to Celebrate 50 Years; Sponsorships Available
- Care Dental Implant & Cosmetic Center's New Website Launch!
- $4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression, PTSD: NRx: Stock Symbol: NRXP
- L-Tron heads to the 2025 IACP Technology Conference in Indianapolis, IN
- Local Roofer Urges Blanchard Homeowners to Schedule Roof Inspections After Severe Hail Storm
- Miami Valley Urban League Announces their 2025 Pillar Award Recipients
- W. Scout Robinson, MD, Joins AAIC - Allergy, Asthma and Immunology Center
- CryoStork®: The Series of Dry Shippers
- Creative Colony Spaces Launches Dedicated Office and Community Support Program for Nonprofits in Silver Spring
- FAN EXPO Philadelphia and School District Team Up to Spotlight Young Artists at Major Convention
- CIMdata to Join a Web Session Covering Key Topics at the Forefront of the Current PLM Landscape
- Tamala Baldwin and BLKG TV Host Free Screenwriting Wellness Workshop in Gwinnett
- Kwizda Pharma Adopts CARA Life Sciences Platform for Rapid QMS Implementation with Minimal IT Resources
- YMCA Seeks to Expand Civic Leadership Opportunities for More New Jersey Youth
- Swim Stroke Doctor, Secures Patent for Groundbreaking Swim Cap That Improves Performance Through
- Solar Refrigerator Company Price Cuts on Danfoss Secop, Solar Lithium Batteries & Solar Fridges